Hepatitis C Articles (HCV)
Back
	Inhbitex nucleotide in Phase 2       INX-189 ... - Inhibitex is a clinical-stage biopharmaceutical company. www.inhibitex.com/Pipeline/Hepatitis.htm Data from the Phase 1a trial indicated that INX-189 was generally well tolerated at all dose ... INX-189, dosed once-daily at 9, 25, 50 and 100 mg for seven days,   Inhibitex Reports Positive Safety and Antiviral Data from Its Phase ... www.natap.org/2011/EASL/EASL_90.htm - Apr 3, 2011 - INX-189, dosed once-daily at 9, 25, 50 and 100 mg for seven days, demonstrated potent and dose-dependent antiviral activity with median           View Older Articles   Back to Top   www.natap.org